$76.97 +0.88 (%) Synageva BioPharma Corp - NASDAQ

Oct. 24, 2014 | 04:00 PM

Partner Headlines

  1. Synageva BioPharma Presents Sebelipase Alfa Data At The NASPGHAN Meeting

    Benzinga | Oct. 23, 2014 | 16:18PM EST
  2. Synageva Shares Tumble Amid Positive Phase 3 Data, A Director's 75% Gain & Analyst Concerns

    Benzinga | Jul. 2, 2014 | 06:47AM EST
  3. Acuity Brands Drops On Downbeat Results; GoPro Shares Surge

    Benzinga | Jul. 1, 2014 | 15:09PM EST
  4. Mid-Day Market Update: Acuity Brands Drops On Downbeat Results; GoPro Shares Surge

    Benzinga | Jul. 1, 2014 | 12:22PM EST
  5. Markets Surge; GM June Sales Rise 1%

    Benzinga | Jul. 1, 2014 | 10:23AM EST
  6. Morning Market Losers

    Benzinga | Jul. 1, 2014 | 09:46AM EST
  7. SYNAGEVA BIOPHARMA

    IBD | Jun. 30, 2014 | 18:52PM EST
  8. Synageva BioPharma Reports Phase 3 Study Meets Primary Endpoint And Six Secondary Endpoints Across Multiple Disease-Related Abnormalities

    Benzinga | Jun. 30, 2014 | 16:03PM EST
  9. UPDATE: Morgan Stanley Reiterates on Synageva BioPharma as Brain-Blood Barrier Study is Good Next Step

    Benzinga | Apr. 1, 2014 | 09:29AM EST
  10. UPDATE: Synageva Biopharma™ Announces 2M Share Proposed Public Offering of Its Common Stock

    Benzinga | Mar. 4, 2014 | 16:32PM EST
  11. Synageva BioPharma Completes Target Enrollment in Phase 3 ARISE Trial

    Benzinga | Dec. 2, 2013 | 16:09PM EST
  12. Benzinga's Top Initiations

    Benzinga | Nov. 15, 2013 | 08:30AM EST
  13. UPDATE: Goldman Sachs initiates on Synageva Following Positive Phase II Data On Sebelipase

    Benzinga | Nov. 15, 2013 | 07:47AM EST
  14. UPDATE: Leerink Swann Downgrades Synageva BioPharma Corp. on Lack of NT News Flow, Market Opportunity Visibility

    Benzinga | Oct. 22, 2013 | 10:44AM EST
  15. UPDATE: Wedbush Downgrades Synageva BioPharma on Valuation

    Benzinga | Oct. 7, 2013 | 10:55AM EST
  16. Benzinga's Volume Movers

    Benzinga | Sep. 25, 2013 | 10:26AM EST
  17. Synageva BioPharma Prices 2.75M Share Offering at $56.63/Share

    Benzinga | Sep. 24, 2013 | 19:48PM EST
  18. Synageva BioPharma Corp (GEVA) SVP, CFO Carsten Boess sells 9,927 Shares

    GuruFocus | Jan. 22, 2013 | 07:06AM EST
  19. UPDATE: Piper Jaffray Reiterates Neutral Rating, Lowers PT on Synageva BioPharma Corp.

    Benzinga | Jan. 4, 2013 | 06:59AM EST
  20. Synageva Prices 2.15M Share Public Offering at $47.53/Share

    Benzinga | Jan. 3, 2013 | 12:43PM EST
  21. UPDATE: Piper Jaffray Downgrades Synageva to Neutral on Lack of Near-Term Catalysts

    Benzinga | Jan. 3, 2013 | 02:30AM EST
  22. Synageva BioPharma Corp (GEVA) President & CEO Sanj K Patel sells 60,000 Shares

    GuruFocus | Dec. 17, 2012 | 13:37PM EST
  23. Synageva BioPharma Corp (GEVA) President & CEO Sanj K Patel sells 35,000 Shares

    GuruFocus | Dec. 6, 2012 | 11:37AM EST
  24. Synageva BioPharma Corp (GEVA) President & CEO Sanj K Patel sells 35,000 Shares

    GuruFocus | Dec. 4, 2012 | 11:38AM EST
  25. UPDATE: Wedbush Securities Reiterates Outperform Rating, Raises PT on Synageva BioPharma Corp.

    Benzinga | Nov. 7, 2012 | 01:53AM EST
  26. Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)

    Benzinga | Oct. 3, 2012 | 08:57AM EST
  27. Benzinga's Top Initiations

    Benzinga | Sep. 6, 2012 | 01:27AM EST
  28. Synageva BioPharma Corp (GEVA) President & CEO Sanj K Patel sells 70,000 Shares

    GuruFocus | Sep. 5, 2012 | 14:13PM EST
  29. Synageva BioPharma Corp (GEVA) President & CEO Sanj K Patel sells 70,000 Shares

    GuruFocus | Sep. 5, 2012 | 14:13PM EST
  30. Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)

    Benzinga | Sep. 5, 2012 | 09:34AM EST
  31. Synageva BioPharma Corp. (GEVA) SVP, CFO Carsten Boess sells 6,618 Shares

    GuruFocus | Jul. 20, 2012 | 14:13PM EST
  32. Merck &, Quest Diagnostics Among Stocks Setting 52-Week Highs Thursday

    FoxBusiness | Jul. 12, 2012 | 06:48AM EST
  33. Synageva BioPharma, WesBanco Hit 52-week Highs Wednesday

    FoxBusiness | Jul. 11, 2012 | 11:13AM EST
  34. Synageva BioPharma, Deltek Hit 52-week Highs Tuesday

    FoxBusiness | Jul. 10, 2012 | 10:33AM EST
  35. ASML, Wolverine World Wide Included in Stocks Up on High Volume Tuesday

    FoxBusiness | Jul. 10, 2012 | 06:33AM EST
  36. Synageva BioPharma Announces $80 Million Proposed Public Offering of Common Stock

    Benzinga | Jul. 9, 2012 | 10:18AM EST
  37. Four Winning Trades Based on Analyst Calls

    Benzinga | Jun. 29, 2012 | 08:36AM EST
  38. CF Industries Holdings, SBA Communications Corporation Included in Stocks Up on High Volume Monday

    FoxBusiness | Jun. 25, 2012 | 10:33AM EST
  39. Winning Trades Based on Analyst Ratings for June 25

    Benzinga | Jun. 25, 2012 | 07:42AM EST
  40. Synageva BioPharma Jumps on Canaccord Genuity Initiation

    Benzinga | Jun. 25, 2012 | 06:34AM EST
  41. Quest Software, Pharmacyclics, Other Stocks Hit 52-Week Highs Monday

    FoxBusiness | Jun. 25, 2012 | 06:32AM EST
  42. UPDATE: Canaccord Genuity Initiates Synageva BioPharma at BUy, $60 PT; Attractive Orphan Platform

    Benzinga | Jun. 25, 2012 | 02:32AM EST
  43. Synageva BioPharma Corp. (GEVA) President & CEO Sanj K Patel sells 50,000 Shares

    GuruFocus | Jun. 5, 2012 | 14:23PM EST
  44. Synageva BioPharma Announces Interim Data at 8th Annual Lysosomal Disease Network World Symposium

    Benzinga | Feb. 9, 2012 | 09:15AM EST
Trading Center